title: Retinoic acid-induced premature osteoblast-to-preosteocyte transitioning has multiple effects on calvarial development.
abstract: We have previously shown that, in human and zebrafish, hypomorphic mutations of the gene encoding the retinoic acid (RA)-metabolizing enzyme Cyp26b1 result in coronal craniosynostosis, caused by an RA-induced premature transitioning of suture osteoblasts to preosteocytes, inducing ectopic mineralization of the suture's osteoid matrix. In addition, we showed that human CYP26B1 null patients have more severe and seemingly opposite skull defects, characterized by smaller and fragmented calvaria, but the cellular basis of these defects remained largely unclear. Here, by treating juvenile zebrafish with exogenous RA or a chemical Cyp26 inhibitor in the presence or absence of osteogenic cells or bone-resorbing osteoclasts, we demonstrate that both reduced calvarial size and calvarial fragmentation are also caused by RA-induced premature osteoblast-to-preosteocyte transitioning. During calvarial growth, the resulting osteoblast deprival leads to decreased osteoid production and thereby smaller and thinner calvaria, whereas calvarial fragmentation is caused by increased osteoclast stimulation through the gained preosteocytes. Together, our data demonstrate that RA-induced osteoblast-to-preosteocyte transitioning has multiple effects on developing bone in Cyp26b1 mutants, ranging from gain to loss of bone, depending on the allelic strength, the developmental stage and the cellular context.
authors.affiliation: Institute of Developmental Biology, University of Cologne, 50674 Cologne, Germany.
authors.forename: Shirine
authors.initials: S
authors.lastname: Jeradi
authors.affiliation: Institute of Developmental Biology, University of Cologne, 50674 Cologne, Germany Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, 50931 Cologne, Germany Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany mhammers@uni-koeln.de.
authors.forename: Matthias
authors.initials: M
authors.lastname: Hammerschmidt
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D052160:Benzothiazoles / Q000494:pharmacology; D002454:Cell Differentiation / Q000502:physiology; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D018507:Gene Expression Regulation, Developmental; D008795:Metronidazole / Q000494:pharmacology; D010006:Osteoblasts / Q000166:cytology*; D010010:Osteoclasts / Q000166:cytology; D010011:Osteocytes / Q000166:cytology*; D010012:Osteogenesis / Q000235:genetics / Q000502:physiology*; D000072516:Retinoic Acid 4-Hydroxylase; D012886:Skull / Q000002:abnormalities / Q000196:embryology*; D014212:Tretinoin / Q000494:pharmacology*; D014230:Triazoles / Q000494:pharmacology; D015027:Zebrafish / Q000196:embryology*; D029961:Zebrafish Proteins / Q000037:antagonists & inhibitors / Q000235:genetics*
chemical_list: D052160:Benzothiazoles; D014230:Triazoles; D029961:Zebrafish Proteins; D008795:Metronidazole; D014212:Tretinoin; D003577:Cytochrome P-450 Enzyme System; D000072516:Retinoic Acid 4-Hydroxylase; C502199:cyp26b1 protein, zebrafish; C406527:R 115866
keywords: Bone development; Diversity; Retinoic acid; Zebrafish